Lambert J, Paul C, Gottlieb A, Poulin Y. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials. J of Skin [Internet]. 2022Nov.16 [cited 2024Jul.3];6(6):s45. Available from: https://jofskin.org/index.php/skin/article/view/1800